Immunogenicity of therapeutic proteins: clinical implications and future prospects (Q35034316)

5 August 2017

1 reference

title

Immunogenicity of therapeutic proteins: clinical implications and future prospects (English)

1 reference

5 August 2017

Huub Schellekens

1

1 reference

5 August 2017

1 November 2002

1 reference

5 August 2017

Clinical Therapeutics

1 reference

5 August 2017

24

1 reference

5 August 2017

1720-40; discussion 1719

1 reference

5 August 2017

11

1 reference

Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Antibody-directed therapy: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Bioequivalence and the immunogenicity of biopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Immunogenicity of rDNA-derived pharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Human immune response to recombinant human proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Clinical significance of antibodies against calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Factor VIII immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Treatment-induced antibodies to interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH--diagnosis and possible alternative treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Neutralising antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Immunogenicity and allergenic potential of animal and human insulins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Immunogenicity of recombinant DNA human insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Immunoregulation and blocking antibodies induced by interferon beta treatment in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Naturally occurring and therapy-induced antibodies to human granulocyte colony-stimulating factor (G-CSF) in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Phase I study of continuous-infusion soluble CD4 as a single agent and in combination with oral dideoxyinosine therapy in children with symptomatic human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Pure red-cell aplasia and recombinant erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Correlation between factor VIII genotype and inhibitor development in hemophilia A.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Clinical significance of insulin antibodies in insulin-treated diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

T-ceIl recognition of discrete regions of the thrombolytic drug streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Towards a quantitative model of immunogenicity: counting pathways in sequence space.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Human pituitary growth hormone and Creutzfeldt-Jakob disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Clinical experience with Somatonorm.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Antibodies to beta-interferons in multiple sclerosis: can we neutralize the controversy?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Leucocyte-derived interferon-alpha in patients with antibodies to recombinant IFN-alpha 2b

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Immunogenicity of biopharmaceuticals in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

An enzyme-linked immunosorbent assay for host cell protein contaminants in recombinant PEGylated staphylokinase mutant SY161.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Directed evolution of proteins by exon shuffling

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980075-3

7 January 2021

10.1016/S0149-2918(02)80075-3

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12501870